SpaceX IPO Creates New Challenges For ETFs (BPTIX, RONB, XOVR, NASA) That Rode Early Stakes Higher

Several exchange-traded funds that built early private-market positions in SpaceX have seen dramatic asset growth ahead of the company’s highly anticipated public listing. Four funds in particular attracted a combined $7.9 billion in net inflows due to their existing private SpaceX holdings, signaling enormous investor appetite for pre-IPO exposure. The funds drawing the most attention…

Read More

GSK (GSK) Seals $10.6 Billion Nuvalent Acquisition In Largest Deal For Cancer Portfolio In Over A Decade

British drugmaker GSK has agreed to acquire U.S.-listed oncology specialist Nuvalent in an all-cash deal valued at $10.6 billion. The transaction values Boston-based Nuvalent at approximately $124 per share, representing a 40% premium to its last closing price. Net of cash acquired, GSK’s aggregate investment is estimated at $9.4 billion, with the deal primarily funded…

Read More